Researchers at Johns Hopkins Kimmel Cancer Center developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
